Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022
Michel Ducreux, Ghassan K. Abou‐Alfa, Tanios Bekaii‐Saab, Jordan Berlin, Andrés Cervantes, Thierry de Baère, Charis Eng, Peter R. Galle, Sharlene Gill, Thomas Gruenberger, Karin Haustermans, Ángela Lamarca, Pierre Laurent‐Puig, Josep M. Llovet, F. Lordick, Teresa Macarulla, Deborah Mukherji, Kei Muro, Radka Obermannová, Juan Manuel O’Connor, Eileen M. O’Reilly, Pia Österlund, P. A. Philip, G. Prager, Érika Ruiz-García, Bruno Sangro, Thomas Seufferlein, Josep Tabernero, Chris Verslype, Harpreet Wasan, Eric Van Cutsem (2023). The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022. ESMO Open, 8(3), pp. 101567-101567, DOI: 10.1016/j.esmoop.2023.101567.
Article406 days agoSO-15 Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Bruno Sangro, Stephen L. Chan, Robin Kate Kelley, George Lau, Masatoshi Kudo, Wattana Sukeepaisarnjaroen, Enrico de Toni, Junji Furuse, Yoon‐Koo Kang, Peter R. Galle, Lorenza Rimassa, Alexandra Heurgué, Vincent C. Tam, Thông Dao, Satheesh Chiradoni Thungappa, В. В. Бредер, Y. Ostapenko, María Reig, M. Makowsky, Charu Gupta, Alejandra Negro, Ghassan K. Abou‐Alfa (2023). SO-15 Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. , 34, DOI: https://doi.org/10.1016/j.annonc.2023.04.487.
Article68 days ago147P Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
S.L. Chan, Bruno Sangro, R.K. Kelley, George Lau, Masatoshi Kudo, Wattana Sukeepaisarnjaroen, Enrico N. De Toni, J. Furuse, Y-K. Kang, Peter R. Galle, Lorenza Rimassa, Alexandra Heurgué, Vincent C. Tam, Tu Van Dao, S. Chiradoni Thungappa, В. В. Бредер, Y.V. Ostapenko, María Reig, Charu Gupta, Ghassan K. Abou‐Alfa (2023). 147P Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC). , 34, DOI: https://doi.org/10.1016/j.annonc.2023.10.282.
Article68 days agoTremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
Ghassan K. Abou‐Alfa, George Lau, Masatoshi Kudo, Stephen L. Chan, Robin Kate Kelley, Junji Furuse, Wattana Sukeepaisarnjaroen, Yoon‐Koo Kang, Tu Van Dao, Enrico N. De Toni, Lorenza Rimassa, В. В. Бредер, Alexander Vasilyev, Alexandra Heurgué, Vincent C. Tam, Kabir Mody, Satheesh Chiradoni Thungappa, Yuriy Ostapenko, Thomas Yau, Sérgio Jobim Azevedo, Marı́a Varela, Ann‐Lii Cheng, Shukui Qin, Peter R. Galle, Sajid Ali, Michelle Marcovitz, Mallory Makowsky, Philip He, John F. Kurland, Alejandra Negro, Bruno Sangro (2022). Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. , 1(8), DOI: https://doi.org/10.1056/evidoa2100070.
Article68 days agoSafety and efficacy of durvalumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from the phase 2 study 22 (NCT02519348).
Ho Yeong Lim, Jeong Heo, Tae‐You Kim, Wai Meng David Tai, Yoon‐Koo Kang, George Lau, Masatoshi Kudo, Won Young Tak, Magdalena Watras, S. Ali, Alejandra Negro, Ghassan K. Abou‐Alfa, Robin Kate Kelley (2022). Safety and efficacy of durvalumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from the phase 2 study 22 (NCT02519348).. , 40(4_suppl), DOI: https://doi.org/10.1200/jco.2022.40.4_suppl.436.
Article68 days ago